EnteroMedics (ETRM) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Caterpillar names Derrick York to lead Resource Industries
- Intel shares drop on foundry risks, sector pressures
EnteroMedics Reports Second Quarter 2015 Financial Results
August 6, 2015 7:01 AM EDTST. PAUL, Minn., Aug. 6, 2015 /PRNewswire/ --Â EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and six months ended June 30, 2015.
For the three months ended June 30, 2015, the Company reported its first U.S. sales of $79,000 with gross profits totaling $48,000. The Company reported a net loss of $7.4 million, or $0.10 per share, including selling, general and administrative expenses of $4.9 million and research and development expenses of $2.5 million. For the six months ended June... More



